BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Medina J, Jones EA, García-Monzón C, Moreno-Otero R. Immunopathogenesis of cholestatic autoimmune liver diseases. Eur J Clin Invest. 2001;31:64-71. [PMID: 11168440 DOI: 10.1046/j.1365-2362.2001.00765.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Jones EA. Rationale for trials of long-term mycophenolate mofetil therapy for primary biliary cirrhosis. Hepatology 2002;35:258-62. [PMID: 11826397 DOI: 10.1053/jhep.2002.31607] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
2 Jiang XH, Zhong RQ, Fan XY, Hu Y, An F, Sun JW, Kong XT. Characterization of M2 antibodies in asymptomatic Chinese population. World J Gastroenterol 2003; 9(9): 2128-2131 [PMID: 12970922 DOI: 10.3748/wjg.v9.i9.2128] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
3 Medina J, Arroyo AG, Sánchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004;39:1185-95. [PMID: 15122744 DOI: 10.1002/hep.20193] [Cited by in Crossref: 164] [Cited by in F6Publishing: 146] [Article Influence: 9.1] [Reference Citation Analysis]
4 Kotb MA, El Henawy A, Talaat S, Aziz M, El Tagy GH, El Barbary MM, Mostafa W. Immune-mediated liver injury: prognostic value of CD4+, CD8+, and CD68+ in infants with extrahepatic biliary atresia. J Pediatr Surg. 2005;40:1252-1257. [PMID: 16080928 DOI: 10.1016/j.jpedsurg.2005.05.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
5 Jiang XH, Zhong RQ, Yu SQ, Hu Y, Li WW, Kong XT. Construction and expression of a humanized M2 autoantigen trimer and its application in the diagnosis of primary biliary cirrhosis. World J Gastroenterol 2003; 9(6): 1352-1355 [PMID: 12800255 DOI: 10.3748/wjg.v9.i6.1352] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
6 Boomkens SY, de Rave S, Pot RG, Egberink HF, Penning LC, Rothuizen J, Zondervan PE, Kusters JG. The role of Helicobacter spp. in the pathogenesis of primary biliary cirrhosis and primary sclerosing cholangitis. FEMS Immunol Med Microbiol. 2005;44:221-225. [PMID: 15866219 DOI: 10.1016/j.femsim.2004.11.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
7 Gómez-Dominguez E, Mendoza J, García-Buey L, Trapero M, Gisbert JP, Jones EA, Moreno-Otero R. Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis. Aliment Pharmacol Ther. 2008;27:441-447. [PMID: 18081731 DOI: 10.1111/j.1365-2036.2007.03585.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
8 Sanz-cameno P, Medina J, Garcı́a-buey L, Garcı́a-sánchez A, Borque MJ, Martı́n-vı́lchez S, Gamallo C, Jones E, Moreno-otero R. Enhanced intrahepatic inducible nitric oxide synthase expression and nitrotyrosine accumulation in primary biliary cirrhosis and autoimmune hepatitis. Journal of Hepatology 2002;37:723-9. [DOI: 10.1016/s0168-8278(02)00266-0] [Cited by in Crossref: 67] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
9 Medina J, Moreno-Otero R. Pathophysiological basis for antioxidant therapy in chronic liver disease. Drugs. 2005;65:2445-2461. [PMID: 16296871 DOI: 10.2165/00003495-200565170-00003] [Cited by in Crossref: 121] [Cited by in F6Publishing: 102] [Article Influence: 7.6] [Reference Citation Analysis]
10 Blum HE. Chronic cholestatic liver diseases: Chronic cholestatic liver diseases. Journal of Gastroenterology and Hepatology 2002;17:S399-402. [DOI: 10.1046/j.1440-1746.17.s3.34.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Marzorati S, Invernizzi P, Lleo A. Making Sense of Autoantibodies in Cholestatic Liver Diseases. Clinics in Liver Disease 2016;20:33-46. [DOI: 10.1016/j.cld.2015.08.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
12 Chaparro M, Sanz-cameno P, Trapero-marugán M, García-buey L, Moreno-otero R. Mechanisms of angiogenesis in chronic inflammatory liver disease. Annals of Hepatology 2007;6:208-13. [DOI: 10.1016/s1665-2681(19)31900-3] [Cited by in Crossref: 31] [Article Influence: 2.1] [Reference Citation Analysis]
13 Medina J, Sanz-Cameno P, García-Buey L, Martín-Vílchez S, López-Cabrera M, Moreno-Otero R. Evidence of angiogenesis in primary biliary cirrhosis: an immunohistochemical descriptive study. J Hepatol. 2005;42:124-131. [PMID: 15629517 DOI: 10.1016/j.jhep.2004.09.024] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 4.2] [Reference Citation Analysis]
14 Gisbert JP, Jones EA, Pajares JM, Moreno-otero R. Is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)?: REVIEW: TREATMENT OF AUTOIMMUNE CHOLANGITIS. Alimentary Pharmacology & Therapeutics 2003;17:17-27. [DOI: 10.1046/j.1365-2036.2003.01381.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]